Avidity Biosciences, Inc. announced on January 4, 2022, Joseph Baroldi informed the company of his intention to resign as Chief Operating Officer of the Company to pursue a new opportunity. His last day at the Company will be January 21, 2022. The Company has entered into a post-employment consulting agreement with Mr. Baroldi for a term of six months.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.94 USD | +0.90% | +5.00% | +208.73% |
06-05 | Avidity Biosciences Insider Sold Shares Worth $767,780, According to a Recent SEC Filing | MT |
05-17 | Avidity Biosciences Insider Sold Shares Worth $2,121,045, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+208.73% | 2.67B | |
+0.99% | 91.72B | |
0.00% | 39.44B | |
-8.52% | 34.47B | |
+65.40% | 26.7B | |
-17.37% | 15.13B | |
-5.99% | 13.27B | |
-10.69% | 11.74B | |
-47.78% | 10.54B | |
+8.09% | 9.41B |
- Stock Market
- Equities
- RNA Stock
- News Avidity Biosciences, Inc.
- Avidity Biosciences, Inc. Announces Resignation of Joseph Baroldi as Chief Operating Officer, Effective January 22, 2022